Mechanism of c-MET in Non-small Cell Lung Cancer and Its Treatment and Testing
10.3779/j.issn.1009-3419.2015.12.06
- VernacularTitle:c-MET在非小细胞肺癌中的作用机制及其治疗和检测
- Author:
LIANG HONGGE
1
;
WANG MENGZHAO
Author Information
1. 中国医学科学院中国协和医科大学北京协和医学院呼吸内科
- Keywords:
Lung neoplasms;
c-MET;
HGF;
Treatment;
Testing
- From:
Chinese Journal of Lung Cancer
2015;(12):745-751
- CountryChina
- Language:Chinese
-
Abstract:
Hepatocyte growth factor/c-MET (HGF/c-MET) signaling pathway can be abnormal activated by many mechanisms such asc-MET mutation, ampliifcation and the overexpression of HGF, and it plays an important role in the development of non-small cell lung cancer (NSCLC), as well as in the tolerance of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) in NSCLC. hTerefore, c-MET is a new molecular target for the therapy of NSCLC since EGFR and ALK. At present, although the c-MET inhibitors have shown a potential prospect in some clinical trials, its assessment of safety and effectiveness in clinical applications, and the choice of testing methods and standards still need a further discussion. In this paper, we summarized the mechanism of c-MET in NSCLC, as well as its treatment prospect and selection of testing methods.
